Literature DB >> 33550636

Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures.

Myriam Abdennadher1,2, Sara Inati1, Ariane Soldatos1, Gina Norato1, Eva H Baker3, Audrey Thurm4, Luca Bartolini1,5, Ruturaj Masvekar6, William Theodore1, Bibiana Bielekova6, Forbes D Porter7, An N Dang Do7.   

Abstract

CLN3 disease is a pediatric neurodegenerative condition wherein seizures are common. The most common disease-causing variant is an ~1-kb deletion in CLN3. We investigated seizure phenotype in relation to genotype and to adaptive behavior, MR spectroscopy and CSF biochemical markers in a CLN3 cohort. We performed seizure phenotyping using clinical history, EEG, and the Unified Batten Disease Rating Scale (UBDRS) seizure score. We assessed correlations of seizure severity with disease severity (UBDRS capability), adaptive behavior composite score (ABC; Vineland-3), glutamate+glutamine+GABA and N-acetylaspartate+N-acetylaspartyl glutamate (MR spectroscopy), and CSF neurofilament light chain (NEFL) levels. In 20 participants, median age was 10.7 years (IQR = 7.8). Eighteen completed baseline EEG; 12 had a 1-year follow-up. Seizures were reported in 14 (8 1-kb deletion homozygotes), with median age at onset of 10.0 (IQR = 6.8). Epileptiform discharges were noted in 15 (9 homozygotes). Bilateral tonic clonic (n = 11) and nonmotor seizures (n = 7) were most common. UBDRS seizure score correlated with age (rp = 0.50; [0.08,0.77]; P = .02), UBDRS capability (rp = -0.57; [-0.81,-0.17]; P = .009) and ABC (rp = -0.66; [-0.85,-0.31]; P = .001) scores, glutamate+glutamine+GABA (rp = -0.54; [-0.80,-0.11]; P = .02) and N-acetylaspartate+N-acetylaspartyl glutamate (rp = -0.54; [-0.80,-0.11]; P = .02), and CSF NEFL (rp = 0.65; [0.29,0.85]; P = .002) levels. After controlling for age, correlations with ABC and CSF NEFL remained significant. In our CLN3 cohort, seizures and epileptiform discharges were frequent and often started by age 10 years without significant difference between genotypes. ABC and CSF NEFL correlate with UBDRS seizure score, reflecting the role of seizures in the neurodegenerative process. Longitudinal evaluations in a larger cohort are needed to confirm these findings.
© 2021 SSIEM.

Entities:  

Keywords:  EEG; MRS; UBDRS; adaptive behavior; batten disease; natural history; neurofilament light chain

Mesh:

Substances:

Year:  2021        PMID: 33550636      PMCID: PMC9437865          DOI: 10.1002/jimd.12366

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  29 in total

1.  Females experience a more severe disease course in Batten disease.

Authors:  Jennifer Cialone; Heather Adams; Erika F Augustine; Frederick J Marshall; Jennifer M Kwon; Nicole Newhouse; Amy Vierhile; Erika Levy; Leon S Dure; Katherine R Rose; Denia Ramirez-Montealegre; Elisabeth A de Blieck; Jonathan W Mink
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

Review 2.  Research challenges in central nervous system manifestations of inborn errors of metabolism.

Authors:  P I Dickson; A R Pariser; S C Groft; R W Ishihara; D E McNeil; D Tagle; D J Griebel; S G Kaler; J W Mink; E G Shapiro; K J Bjoraker; L Krivitzky; J M Provenzale; A Gropman; P Orchard; G Raymond; B H Cohen; R D Steiner; S F Goldkind; R M Nelson; E Kakkis; M C Patterson
Journal:  Mol Genet Metab       Date:  2010-12-02       Impact factor: 4.797

3.  Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan.

Authors:  Vibeke Arntsen; John Strandheim; Ingrid B Helland; Trond Sand; Eylert Brodtkorb
Journal:  Epilepsy Behav       Date:  2019-03-16       Impact factor: 2.937

4.  A clinical rating scale for Batten disease: reliable and relevant for clinical trials.

Authors:  F J Marshall; E A de Blieck; J W Mink; L Dure; H Adams; S Messing; P G Rothberg; E Levy; T McDonough; J DeYoung; M Wang; D Ramirez-Montealegre; J M Kwon; D A Pearce
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

5.  Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.

Authors:  Robert S Fisher; J Helen Cross; Jacqueline A French; Norimichi Higurashi; Edouard Hirsch; Floor E Jansen; Lieven Lagae; Solomon L Moshé; Jukka Peltola; Eliane Roulet Perez; Ingrid E Scheffer; Sameer M Zuberi
Journal:  Epilepsia       Date:  2017-03-08       Impact factor: 5.864

6.  Progressive myoclonic epilepsies: definitive and still undetermined causes.

Authors:  Silvana Franceschetti; Roberto Michelucci; Laura Canafoglia; Pasquale Striano; Antonio Gambardella; Adriana Magaudda; Paolo Tinuper; Angela La Neve; Edoardo Ferlazzo; Giuseppe Gobbi; Anna Teresa Giallonardo; Giuseppe Capovilla; Elisa Visani; Ferruccio Panzica; Giuliano Avanzini; Carlo Alberto Tassinari; Amedeo Bianchi; Federico Zara
Journal:  Neurology       Date:  2014-01-02       Impact factor: 9.910

7.  Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2014-11-11       Impact factor: 5.449

8.  Spatial extent of neuronal metabolic dysfunction measured by proton MR spectroscopic imaging in patients with localization-related epilepsy.

Authors:  L M Li; F Cendes; F Andermann; F Dubeau; D L Arnold
Journal:  Epilepsia       Date:  2000-06       Impact factor: 5.864

9.  Neuronal ceroid lipofuscinoses: clinical and EEG findings in a large study of Italian cases.

Authors:  E Veneselli; R Biancheri; M V Perrone; S Buoni; A Fois
Journal:  Neurol Sci       Date:  2000       Impact factor: 3.307

10.  Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy.

Authors:  Giulio Disanto; Chiara Prosperetti; Claudio Gobbi; Christian Barro; Zuzanna Michalak; Tiziano Cassina; Jens Kuhle; Gabriele Casso; Pamela Agazzi
Journal:  Epilepsy Behav       Date:  2019-07-30       Impact factor: 2.937

View more
  1 in total

1.  Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.

Authors:  Katharina Iwan; Nina Patel; Amanda Heslegrave; Mina Borisova; Laura Lee; Rebecca Bower; Sara E Mole; Philippa B Mills; Henrik Zetterberg; Kevin Mills; Paul Gissen; Wendy E Heywood
Journal:  F1000Res       Date:  2021-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.